drugset / Trial / NCT07308782
A Phase Ⅱa Clinical Study of CL-197 Capsules
NaSequentialOpen-labelTreatment
Summary
This study will evaluate the antiretroviral activity, safety and pharmacokinetics of single dose of CL-197 capsule in three dose groups administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.
Timeline
- Start
- 2025-11-29
- Primary completion
- 2026-12
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CL-197 | Unknown | 10 mg | Oral |
| Subject | CL-197 | Unknown | 30 mg | Oral |
| Subject | CL-197 | Unknown | 60 mg | Oral |